Acadia Pharmaceuticals Inc
ACAD· Nasdaq
ACADAcadia Pharmaceuticals Inc
Released Nov 2, 2023, after the close
10-Q filed Nov 3, 2023, 34 days after period end · 0000950170-23-058436
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $211.70M | $130.71M | $131.61M | $120.58M |
| Net Income | -$65.18M | -$27.18M | -$14.46M | -$84.66M |
| EPS Diluted |
Acadia Pharmaceuticals Inc · CIK 1070494 · Engraved from SEC EDGAR
| -$0.40 |
| -$0.17 |
| -$0.09 |
| -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
